Concentra Group Holdings Parent Inc

Concentra Group Holdings Parent Inc (CON) Stock Analysis

$34.260

-0.435 (-1.27%)At close

Loading chart…
High
34.920
Open
34.920
VWAP
34.46
Vol
508.13K
Mkt Cap
Low
34.192
Amount
17.51M
EV/EBITDA, TTM
13.29

Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States. The Company delivers an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. It supports the care of approximately 54,000 patients each business day on average across 46 states and the District of Columbia at its 633 occupational health centers, 415 onsite health clinics at employer worksites, and Concentra Telemed. Its segments include Occupational health centers, Onsite health clinics, and Other businesses. Occupational health centers segment encompasses the services that it delivers at its occupational health center facilities across the United States. Onsite health clinics segment delivers occupational health services and/or employer-sponsored primary care services. The Other businesses segment comprises several complementary services, such as Concentra Pharmacy, and Concentra Medical Compliance Administration.

AI analysis of Concentra Group Holdings Parent Inc (CON)

buy

Concentra Group Holdings Parent Inc is a good buy right now due to its current price of $34.26, which is below the analyst price targets ranging from $40 to $42, indicating significant upside potential. The company reported a strong Q2 2026 revenue of $606 million, reflecting a 10% year-over-year growth, and a net income of $67 million, which is a notable increase. However, the RSI is at 40.77, suggesting the stock is nearing oversold territory, which could indicate a buying opportunity. The main risk is the 5-day price change of -2.11%, indicating recent volatility.

Valuation Metrics

The current forward P/E ratio for Concentra Group Holdings Parent Inc (CON) is 21.05, compared to its 5-year average forward P/E of 16.39.

Forward P/E

Overvalued
5Y Average P/E
16.39
Current P/E
21.05
Overvalued
18.81
Undervalued
13.98

Forward EV/EBITDA

Overvalued
5Y Average EV/EBITDA
11.59
Current EV/EBITDA
13.29
Overvalued
13.16
Undervalued
10.02

Forward P/S

Strongly Overvalued
5Y Average P/S
1.31
Current P/S
1.78
Overvalued
1.47
Undervalued
1.14

Whales holding CON

H

HBK Investments L.P.

+ HoldingCON

+4.39%

3M Return

C

Cramer Rosenthal McGlynn LLC

+ HoldingCON

-0.09%

3M Return

Events Timeline

2026-07-20 (ET)

11:00:00

Concentra Opens First Medical Center in Idaho

2026-07-13 (ET)

09:31:00

Concentra Opens New Medical Center in Missouri

2026-05-07 (ET)

16:40:00

Raises FY26 Adjusted EBITDA Outlook to $460M-$480M

16:40:00

Concentra Q1 Revenue $569.6M Exceeds Expectations

2026-04-14 (ET)

16:40:00

Concentra Executive Anderson Announces Retirement

News

CON FAQ — answered by Alphio AI

Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States. The Company delivers an extensive suite of services, including occupational and consumer health services and other direct-to-employer care. It supports the care of approximately 54,000 patients each business day on average across 46 states and the District of Columbia at its 633 occupational health centers, 415 onsite health clinics at employer worksites, and Concentra Telemed. Its segments include Occupational health centers, Onsite health clinics, and Other businesses. Occupational health centers segment encompasses the services that it delivers at its occupational health center facilities across the United States. Onsite health clinics segment delivers occupational health services and/or employer-sponsored primary care services. The Other businesses segment comprises several complementary services, such as Concentra Pharmacy, and Concentra Medical Compliance Administration. It operates in the Healthcare sector.

Concentra Group Holdings Parent Inc is a good buy right now due to its current price of $34.26, which is below the analyst price targets ranging from $40 to $42, indicating significant upside potential. The company reported a strong Q2 2026 revenue of $606 million, reflecting a 10% year-over-year growth, and a net income of $67 million, which is a notable increase. However, the RSI is at 40.77, suggesting the stock is nearing oversold territory, which could indicate a buying opportunity. The main risk is the 5-day price change of -2.11%, indicating recent volatility.

This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.

Get Started